Teniposide (Vumon)
General information
Class/mechanism: Topoisomerase II inhibitor. Teniposide inhibits type II topoisomerase, which results in single and double-stranded DNA breaks and DNA-protein crosslinks. It is cell-cycle specific, acting in late S or early G2, preventing cells from entering mitosis. It is dissolved in Cremophor EL (polyoxyethylated castor oil), which may cause hypersensitivity infusion reactions.[1][2]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- B-cell acute lymphoblastic leukemia
- Burkitt lymphoma
- CNS lymphoma
- HIV-associated lymphoma
- Low-grade glioma
- Small cell lung cancer
Diseases for which it was used
Patient drug information
- Teniposide (Vumon) patient drug information (Chemocare)[3]
- Teniposide (Vumon) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 1992-07-14: Initial approval for induction therapy in patients with refractory childhood acute lymphoblastic leukemia
History of changes in EMA indication
- 1976-04-05: EURD
Also known as
- Code name: VM-26
- Brand name: Vumon
References
- Drugs
- Intravenous medications
- Irritant
- Topoisomerase II inhibitors
- B-cell acute lymphoblastic leukemia medications
- Burkitt lymphoma medications
- CNS lymphoma medications
- HIV-associated lymphoma medications
- Low-grade glioma medications
- Small cell lung cancer medications
- Diffuse large B-cell lymphoma medications (historic)
- Follicular lymphoma medications (historic)
- FDA approved in 1992
- EMA approved in 1976